Indications |
Intravenous Heart failure Adult: Loading dose: 750 mcg/kg by slow inj over 2-3 min (may be repeated after 30 minutes if necessary). Maintenance: 5-10 mcg/kg/min by infusion. Max cumulative dose: 10 mg/kg in 24 hr. Incompatibility: Incompatible with glucose-containing solutions and furosemide. |
Contraindications |
Hypersensitivity. |
Warnings / Precautions |
Obstructive pulmonary or aortic disease, hypertrophic cardiomyopathy; BP and heart rate monitored during drug administration; fluid and electrolyte balance should be maintained; platelet counts and liver function should be monitored; protect amp from light. Pregnancy and lactation. |
Adverse Reactions |
GI disturbances, nausea, vomiting, thrombocytopaenia, hypotension, chest pain, hypersensitivity, myositis, vasculitis, nail discoloration, Inj site pain, decreased tear production. Potentially Fatal: Cardiac arrhythmia, hepatotoxicity. |
Overdose Reactions |
May result in severe hypotension. General supportive and symptomatic treatment, including circulatory support, should also be initiated as necessary. |
Drug Interactions |
Chemical interaction with precipitation occurs with amrinone and dextrose or furosemide. Thus drug mixing should be avoided. Potentially Fatal: Concurrent usage with disopyramide may lead to severe hypotension. See Below for More amrinone Drug Interactions |
Mechanism of Actions |
Amrinone is a phosphodiesterase inhibitor which has vasodilating and positive inotropic properties. It causes an increase in cyclic adenosine monophosphate conc leading to greater contractile force in cardiac muscle. Distribution: 10-22% bound to plasma proteins. Half-life after IV admin: 4-6 hr. Metabolism: Partially metabolised in liver. Excretion: 40% excreted unchanged. |
Storage Conditions |
Intravenous: Store at 15-30°C. |
ATC Classification |
C01CE01 - amrinone ; Belongs to the class of phosphodiesterase inhibitors. Used in the treatment of heart failure. |
Storage |
Intravenous: Store at 15-30°C. |
Available As |
|
Amrinone
Post Review about Amrinone Click here to cancel reply.
Amrinone Containing Brands
Amrinone is used in following diseases
Drug - Drug Interactions of Amrinone
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.